PORTAS 2, Comparing Venae Sectio Versus Punction of Vena Subclavia for Insertion of a Totally Implantable Access Port
Launched by HEIDELBERG UNIVERSITY · Jan 24, 2008
Trial Information
Current as of June 17, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age equal or greater than 18 years
- • Patients scheduled for primary elective implantation of TIAP
- Exclusion Criteria:
- • Participation in another clinical trial which could interfere with the primary endpoint of this study
- • Lack of compliance
- • Impaired mental state or language problem
- • Patients with known allergy to contrast agent
About Heidelberg University
Heidelberg University, a prestigious institution located in Germany, is renowned for its commitment to advancing medical research and clinical innovation. With a strong emphasis on interdisciplinary collaboration, the university fosters a dynamic environment for conducting clinical trials that aim to enhance patient care and improve health outcomes. Leveraging cutting-edge technology and a robust network of healthcare professionals, Heidelberg University is dedicated to exploring novel therapeutic approaches and contributing to the global medical community through rigorous scientific inquiry and ethical research practices.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Heidelberg, Baden Würtemberg, Germany
Patients applied
Trial Officials
Markus W Büchler, Prof. Dr.
Principal Investigator
University of Heidelberg, Department of General, Visceral and Transplantation Surgery
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials